Regenxbio Inc (NAS:RGNX)
$ 8.92 0.16 (1.83%) Market Cap: 440.86 Mil Enterprise Value: 228.13 Mil PE Ratio: 0 PB Ratio: 1.26 GF Score: 65/100

Q1 2019 Regenxbio Inc Earnings Call Transcript

May 07, 2019 / 08:30PM GMT
Release Date Price: $49.88 (-4.66%)
Operator

Good afternoon, and welcome to the REGENXBIO First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Mr. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO. You may begin.

Patrick J. Christmas
REGENXBIO Inc. - Senior VP & Chief Legal Officer

Good afternoon and thank you for joining us today. With us today are Ken Mills, REGENXBIO's President and Chief Executive Officer; Steve Pakola, our Chief Medical Officer and Vit Vasista, our Chief Financial Officer.

Earlier this afternoon, REGENXBIO released financial and operating results for the 3 months ended March 31, 2019. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today's conference call will include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot